Aspira Women’s Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23

Rhea-AI Summary

Aspira Women’s Health (AWH) will report its financial results for the year ended December 31, 2021, on March 23, 2022, prior to market opening. A conference call with investors is scheduled for 8:30 AM ET on the same day to discuss the results and provide corporate updates. Aspira specializes in innovative women's health solutions, particularly focusing on ovarian cancer risk assessment and pelvic diseases. With over a decade of expertise, they are advancing their portfolio with new products like OVAWatch and EndoCheck, aiming to enhance gynecologic health outcomes.

Positive

• Focus on ovarian cancer risk assessment with OVA1plus and Aspira GenetiX offerings.
• Development of new products like OVAWatch and EndoCheck to enhance service portfolio.
• Launch of Aspira Synergy technology for improved patient access to testing.

Negative

• None.

AUSTIN, Texas, March 15, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:

Conference Call & Webcast Details
Date:	Wednesday, March 23
Time:	8:30am ET
Toll Free:	1-877-407-4018
International:	1-201-689-8471
Conference ID:	13726810
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1527421&tp_key=e6d813f5a1

About Aspira Women’s Health Inc. 
Aspira Women’s Health Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus^TM combines our FDA-cleared products, OVA1^® and OVERA^®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OVAWatch^TM and EndoCheck^TM. To improve patient accessibility, Aspira Women’s Health has recently launched our Aspira Synergy^TM technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
Arr@lifesciadvisors.com

FAQ

When will Aspira Women’s Health release its financial results?

Aspira Women’s Health will release its financial results on March 23, 2022.

What time is the conference call for Aspira Women’s Health's financial results?

The conference call is scheduled for 8:30 AM ET on March 23, 2022.

What products does Aspira Women’s Health focus on?

Aspira Women’s Health focuses on ovarian cancer risk assessment and solutions for pelvic diseases.

What innovative products are being developed by Aspira Women's Health?

Aspira is developing new products such as OVAWatch and EndoCheck.